The latest market report published by Acute Market Reports, Inc. “Global Genital Herpes Treatment Drugs Market – Growth, Future Prospects, Competitive Analysis, 2018 – 2026,” The global market for genital herpes treatment drugs is expected to expand to CAGR by 4.9 per cent from 2018 to 2026.
Genital herpes is the most common form of sexually transmitted disease in sexually active people. No visible symptoms have been reported in the early stage of infection, but as the disease progresses, genital lesions, cold sores, abnormal discharge, and severe pain during urination are clinically manifested. It spreads through oral, vaginal, and anal contact. It is important to note that herpes infection is not cured only the symptoms are suppressed to promote relief in ill patients. Safe sex, early diagnosis and genital hygiene are the best preventive measures to prevent the spread of genital herpes infection. There is a changing trend in the treatment of genital herpes infection, with biologists focusing primarily on developing vaccines to enhance immunity in ill patients and address the problem of lesion recurrence.
Browse Full Report Originally Published by Acute Market Reports at https://www.acutemarketreports.com/report/genital-herpes-treatment-drugs-market
Acyclovir is currently the dominant drug class in the market for genital herpes treatment drugs. The primary characteristics responsible for the dominance of acyclovir are its excellent therapeutic efficacy, dose tolerance with negligible toxicity. It is currently the first choice drug for the treatment of genital herpes with a prescribed dose of 200 mg five times daily for 10 days. Famciclovir has gained prominence due to its higher oral bioavailability used in the treatment of genital herpes patients suffering from recurrence of the lesion.
North America is currently the dominant geographic segment of the market for genital herpes treatment drugs. According to the Center for Disease Control and Prevention (CDC), genital herpes occurs 1 in every 6 citizens in the United States. Rising prevalence of sexually transmitted diseases and effective treatment guidelines drive the growth of the market for genital herpes drugs in North America. Affordable reimbursement scenario and place of work of major players such as AstraZeneca, Plc., GlaxoSmithkline, Plc. & Novartis AG. Propels the growth of the market for genital herpes treatment drugs in the European region. Asia Pacific will see rapid growth during the forecast period from 2018 to 2026 due to an increase in the prevalence of infected HSV-1 patients, an increase in public health awareness and the presence of large generic medicines to treat genital herpes infection.
Pharmaceutical companies providing medication for the treatment of genital herpes infection are AstraZeneca, Plc., Apotheca, Inc., Asahi Kasei Pharma Corporation, Carlsbad Technology, Inc., GlaxoSmithkline, Plc., Mylan N.V., Novartis AG., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd. and Zydus Pharmaceuticals, Inc.
Key Market Movements:
- Rising prevalence of sexually transmitted disease worldwide
- Increasing public health awareness and affordable reimbursement scenario drive the genital herpes treatment drugs market
- Excellent product pipeline catering therapeutics vaccines to bolster patient immunity such as GEN-003 and VCL-HB01
You can get the sample copy of this research by Acute Market Reports here: https://www.acutemarketreports.com/request-free-sample/138527
Report Scope by Segments
By Drug Class (2016–2026; US$ Mn)
- Tabular Representation of Drug Pipeline in Phase II and I
- Phase III Drugs
By Geography Segment (2016-2026; US$ Mn)
- North America
- Asia Pacific (APAC)
- Middle East & Africa (MEA)
- Latin America
Acute Market Reports is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives.
Name: Chris Smith
Address: 105 N 1st ST #429,
SAN JOSE, CA 95103 US
(US/CANADA) Ph.: +1-855-455-8662